DRB – 100 mg

Brand:
Cayman
CAS:
53-85-0
Storage:
-20
UN-No:
Non-Hazardous - /

DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 µM){15211}, Cdk7 (IC50 = ~20 µM){15209,15207}, Cdk8 (IC50 = ~20 µM){15207}, and Cdk9 (IC50 = 3 µM).{15214} Through inhibition of certain CTD kinases, DRB inhibits an elongation step during RNA polymerase II transcription{15210,15208}, which can trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells.{15213} DRB can also inhibit HIV transcription (IC50 = ~4 µM) by targeting elongation enhanced by the HIV-encoded transactivator Tat.{15212}  

 

Available on backorder

SKU: 10010302 - 100 mg Category:

Description

Inhibits CKII (IC50 range of 4-10 µM), Cdk7 (IC50 = ~20 µM), Cdk8 (IC50 = ~20 µM), and Cdk9 (IC50 = 3 µM); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 µM)


Formal name: 5,6-dichloro-1-β-D-ribofuranosyl-1H-benzimidazole

Synonyms:  Benzimidazole|NSC 401575

Molecular weight: 319.1

CAS: 53-85-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Kinase Inhibitors|CK2||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Casein Kinase Signaling||Research Area|Epigenetics, Transcription, & Translation|RNA, DNA, & Protein Synthesis||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS